Efficacy and Mechanism of Core Traditional Chinese Medicines for Treating Malignant Lymphoma Based on Efficacy Studies: A Study Supported by Network Pharmacology and Molecular Docking

Overview

Journal Curr Pharm Des

Publisher Bentham Science Publishers

Date 2024 Jul 31

PMID 39082169

Authors

Jiayue Jin

Simeng Ren

Baojin Han

Wenzheng Zhang

Hongkun Xu

Jingqi Yang

Jie Liu

Affiliations

Soon will be listed here.

Abstract

Background: The burden of malignant lymphoma in China is greater than the global equivalent. The randomized controlled trials provide medical evidence that TCM can improve the response and survival in patients with lymphoma. However, the mechanisms underlying remain undefined.

Objective: Evidence-based data mining for traditional Chinese medicine (TCM) on improving response and survival in malignant lymphoma treatment was performed in this study. In addition, the mechanisms of TCM through network pharmacology and molecular docking were explored.

Methods: The China national knowledge infrastructure, Wanfang Data, China Science and Technology Journal Database, PubMed, and Web of Science databases were searched to select TCM formulas with response and survival benefits in the treatment of malignant lymphomas. We then analyzed and visualized the tropism of taste, frequency of drug use, dosage, clustering, association rules mining (minimum support threshold as 0.20, the minimum confidence threshold as 0.80 and lift >1), and complex networks for potential core herb compositions using Excel, IBM SPSS Statistics 26, and IBM SPSS Modeler 18. TCM systems pharmacology, GeneCards, Online Mendelian Inheritance in Man, and other databases were used to screen potential core active ingredients and malignant lymphoma-related targets. The intersection targets were used to construct a protein interaction network using Cytoscape to obtain the key targets. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment were used to analyze the core target, and molecular docking of key components and targets was performed using CB-Dock2.

Results: Twenty-four Chinese herbal formulae were included, encompassing 107 herbs with mainly cold and warm properties and bitter and sweet flavors. They were associated with the yin meridians of the liver, spleen, and lungs. The TCMs underwent association rule analysis, identified 27 association rules, including 12 herb pairs and 13 angle medicine, and clustered into eight classes by clustering analysis. Combined with the results from mining analysis, Pinelliae (Ban-xia), Poria (Fu-ling), Atractylodis macrocephalae (Bai-zhu), Curcumae (E-zhu), and Sparganii (San-leng) were the potential core herbs According to network pharmacology and molecular docking, the main core components of the potential core drugs are hederagenin, cerevisterol, 14- acetyl-12-senecioyl-2E,8E,10E-atractylentriol, 12,13-epoxy-9-hydroxynonadeca-7,10-dienoic acid, cavidine, and baicalein. These core drugs are mainly involved in the pathways of EGFR tyrosine kinase inhibitor resistance, PD-1/L1, natural killer cell-mediated cytotoxicity, NF-κB, epithelial cell signaling in H. pylori infections, and Th17 cell differentiation. They aid in regulating the transmembrane receptor protein tyrosine kinase signaling pathway, ERBB signaling pathway, PI3K signaling pathway, and phosphorylation process. Ten key components and eight key targets, including baicalein and hederagenin, demonstrated strong binding activity.

Conclusion: Collectively, some core herbs exerted anti-tumor effects through immune and inflammatory pathway modulation, inhibition of immune escape, and induction of cell apoptosis. These findings support future evidence-based research on malignant lymphoma treatment using TCM.

References

Liu W, Liu J, Song Y, Wang X, Mi L, Cai C . Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 2022; 14(7):3175-3190. PMC: 9037266. DOI: 10.18632/aging.204006. View

Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N . Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. Cancer Med. 2020; 9(11):3765-3774. PMC: 7286476. DOI: 10.1002/cam4.3037. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

Choudhary N, Singh V . A census of P. longum's phytochemicals and their network pharmacological evaluation for identifying novel drug-like molecules against various diseases, with a special focus on neurological disorders. PLoS One. 2018; 13(1):e0191006. PMC: 5761900. DOI: 10.1371/journal.pone.0191006. View

Huang Q, Lin J, Huang S, Shen J . Impact of Qi-Invigorating Traditional Chinese Medicines on Diffuse Large B Cell Lymphoma Based on Network Pharmacology and Experimental Validation. Front Pharmacol. 2021; 12:787816. PMC: 8699731. DOI: 10.3389/fphar.2021.787816. View

Luo W, Ding R, Guo X, Zhan T, Tang T, Fan R . Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3. Comput Biol Med. 2022; 145:105457. PMC: 8957363. DOI: 10.1016/j.compbiomed.2022.105457. View

Kim S, Chen J, Cheng T, Gindulyte A, He J, He S . PubChem 2023 update. Nucleic Acids Res. 2022; 51(D1):D1373-D1380. PMC: 9825602. DOI: 10.1093/nar/gkac956. View

Gfeller D, Michielin O, Zoete V . Shaping the interaction landscape of bioactive molecules. Bioinformatics. 2013; 29(23):3073-9. DOI: 10.1093/bioinformatics/btt540. View

Wishart D, Feunang Y, Guo A, Lo E, Marcu A, Grant J . DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2017; 46(D1):D1074-D1082. PMC: 5753335. DOI: 10.1093/nar/gkx1037. View

10.

Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y . TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2023; 52(D1):D1465-D1477. PMC: 10767903. DOI: 10.1093/nar/gkad751. View

11.

Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R . The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2022; 51(D1):D638-D646. PMC: 9825434. DOI: 10.1093/nar/gkac1000. View

12.

Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi A, Tanaseichuk O . Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10(1):1523. PMC: 6447622. DOI: 10.1038/s41467-019-09234-6. View

13.

Liu Y, Yang X, Gan J, Chen S, Xiao Z, Cao Y . CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting. Nucleic Acids Res. 2022; 50(W1):W159-W164. PMC: 9252749. DOI: 10.1093/nar/gkac394. View

14.

Yang X, Liu Y, Gan J, Xiao Z, Cao Y . FitDock: protein-ligand docking by template fitting. Brief Bioinform. 2022; 23(3). DOI: 10.1093/bib/bbac087. View

15.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

16.

Liu W, Liu J, Song Y, Zeng X, Wang X, Mi L . Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12(1):115. PMC: 6862726. DOI: 10.1186/s13045-019-0785-7. View

17.

Green M, Monti S, Rodig S, Juszczynski P, Currie T, ODonnell E . Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116(17):3268-77. PMC: 2995356. DOI: 10.1182/blood-2010-05-282780. View

18.

Twa D, Chan F, Ben-Neriah S, Woolcock B, Mottok A, Tan K . Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014; 123(13):2062-5. DOI: 10.1182/blood-2013-10-535443. View

19.

Elenitoba-Johnson K, Lim M . New Insights into Lymphoma Pathogenesis. Annu Rev Pathol. 2017; 13:193-217. DOI: 10.1146/annurev-pathol-020117-043803. View

20.

Cully M, You H, Levine A, Mak T . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6(3):184-92. DOI: 10.1038/nrc1819. View